Ogden Christopher 4

What Happened Christopher Ogden, Chief Financial Officer of CytomX Therapeutics, sold 1,624 shares on 2026-06-15 at $3.05 per share, generating proceeds of $4,953. The Form 4 states the shares were sold solely to satisfy tax or other government withholding obligations in connection with RSU vesting.

Key Details

• Transaction date & price: 2026-06-15 — 1,624 shares sold at $3.05 each (total $4,953).
• Transaction code: S (sale); footnote F1: sale solely for tax/government withholding on RSU vesting.
• Shares owned after transaction: filing notes inclusion of 167,249 RSUs (footnote F2).
• Filing date/timeliness: Form filed 2026-06-17 — within the typical 2-business-day window (timely).

Context This was a tax-withholding sale tied to RSU vesting, a routine administrative transaction that doesn’t necessarily signal a change in the insider’s view of the company. For investors, outright purchases by insiders are generally more notable than routine sales for tax purposes.